Johnson & Johnson’s Coronavirus Vaccine Protects Monkeys, Study Finds

An experimental coronavirus vaccine developed by Johnson & Johnson protected monkeys from infection in a new study. It is the second vaccine candidate to show promising results in monkeys this week.

The company recently began a clinical trial in Europe and the United States to test its vaccine in people. It is one of more than 30 human trials for coronavirus vaccines underway across the world. But until these trials are complete — which will probably take several months — the monkey data offers the best clues to whether the vaccines will work.

“This week has been good — now we have two vaccines that work in monkeys,” said Angela Rasmussen, a virologist at Columbia University who was not involved in the studies. “It’s nice to be upbeat for a change.”

But she cautioned that the new results shouldn’t be used to rush large-scale trials in humans. “We just can’t take shortcuts,” she said.

Unlike many other vaccines in development that might require two injections, the Johnson & Johnson candidate shielded the monkeys with just one dose, according to a study published on Thursday in Nature.

“It’s a very reassuring level of protection we saw,” said Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical Center in Boston and a co-author of the new study.

The study comes just two days after a similar one was published on a vaccine tested by Moderna and the National Institutes of Health....